Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

STONY BROOK, N.Y.--( BUSINESS WIRE )--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development. The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,' supports the further development of the Company's LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines. An initial manuscript detailing the study's findings was published in preprint form on bioRxiv in July 2022.

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q4 2022 Earnings Conference Call December 14, 2022 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President and Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright & Co, LLC Jason McCarthy - Maxim Group LLC Operator Good afternoon, and welcome to the Applied DNA Sciences Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.

Applied DNA Sciences, Inc. (APDN) Q4 2022 Earnings Call Transcript

STONY BROOK, N.Y.--( BUSINESS WIRE )--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.

Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results

STONY BROOK, N.Y.--( BUSINESS WIRE )--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.

Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022

Applied DNA to Establish North America's First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York

Akero Therapeutics Inc

Avenue Therapeutics

HeartBeam

Immuneering Corp

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

American Virtual Cloud Technologies

FuboTV

Tattooed Chef

22nd Century Group

Best penny stocks to buy right now? The post Best Penny Stocks To Buy Now That CPI Is Out?

Best Penny Stocks To Buy Now That CPI Is Out? 5 For Your Watch List

Sobr Safe Inc

Exela Technologies

Add these penny stocks to your watchlist right now The post Penny Stocks to Buy Right Now? 3 to Watch in Mid-October 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy Right Now? 3 to Watch in Mid-October 2022

Source: Connect world / Shutterstock.com Applied DNA (NASDAQ: APDN ) stock is rocketing higher on Monday after the company announced a massive order for its LinearDNA product. LinearDNA is an enzymatic manufacturing platform that produces DNA without risks of bacterial contamination and non-target DNA sequences.

Why Is Applied DNA (APDN) Stock Up 70% Today?

Toughbuilt Industries Inc

Penny stocks with news today: are they a buy or should you avoid them altogether? The post 3 Hot Penny Stocks To Watch With Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks To Watch With Big News Today

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a global manufacturer of in vitro diagnostics. Under the terms of the repeat order, the Company will deliver quantities of LinearDNA to the custom

Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA' or the “Company”), a leader in polymerase chain reaction (PCR”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a LinearDNA™-based vaccine candidate (the “vaccine candidate”) reduced infectious virus shedding and was protective against SARS-CoV-2 in a challenge trial in ferrets. The p

Applied DNA's Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets

STONY BROOK, N.Y. & ITHICA, N.Y.--(BUSINESS WIRE)---- $APDN #CUCVM--Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA' or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine (“CUCVM”) announced the signing of a research agreement (the “Agreement”) to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications. Primarily, the Agreement seeks to combine LinearDNA

Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022. Applied DNA's CEO and Chairman of the Board of Directors, Dr. James A. Hayward,

Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing. The

Applied DNA Launches Monkeypox Testing Service

Burning Rock Biotech

Graphex Group Ltd

Mobilicom 

Penny stocks to buy according to Reddit sentiment. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 That Redditors Are Watching Now

Aeglea BioTherapeutics

Volcon

Here's what you need to know about trading penny stocks on August 22nd The post Buying Penny Stocks Right Now? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks Right Now? 3 to Watch This Week

TDH Hlds

Summit Therapeutics

Check these tips out for investing in penny stocks in September 2022 The post Investing in Penny Stocks in September? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Investing in Penny Stocks in September? 3 Tips

Party City Holdco

Sonder Holdings

Penny stocks with unusual options activity today. The post 4 Penny Stocks To Watch With Bullish Buys From Options Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With Bullish Buys From Options Traders

Source: Viacheslav Lopatin / Shutterstock.com Applied DNA Sciences (NASDAQ: APDN ) stock is rising higher on Friday after the company sent its monkeypox test to the NYSDOH for approval. According to a press release, Applied DNA's Linea Monkeypox Virus 1.0 Assay is designed to “identify the genetic signature of the Clade II variant of the monkeypox virus that is currently prevalent in the U.S.” Applied DNA is hoping for approval that designates its monkeypox test as an NYSDOH Laboratory Developed Test (LDT).

Applied DNA (APDN) Stock Jumps on Monkeypox Test News

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LDT--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT). The PCR

Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Chimerix

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

SIGA Technologies

Tonix Pharmaceuticals Hld

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 8.33% and 19.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) Reports Q3 Loss, Tops Revenue Estimates

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2022, ended June 30, 2022. The Company's results are in line with preliminary selected quarterly results issued in the Company's Form S-1/A filed on August 1, 2022. “We executed well in the fiscal third quarter, managing our financial results through COVID-19 testing

Applied DNA Reports Third Quarter Fiscal 2022 Financial Results

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LNP--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, the Company's majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular (IM) injection without the concurrent use of electroporation (EP) that utilizes electrical pulses to deliver DNA to target cells. The Company believes tha

Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

News for Applied DNA Sciences Stock (APDN)